Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2
富含亮氨酸重复激酶 2 对单纯疱疹病毒发病机制的调节
基本信息
- 批准号:10300301
- 负责人:
- 金额:$ 19.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-11 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AdultAllelesAntiviral AgentsBacterial InfectionsBindingBiometryBlindnessCell DeathCell LineCellsCorneaCrohn&aposs diseaseCutaneousDataDevelopment PlansDiseaseDisease modelEncephalitisEtiologyEyeFamilyFlow CytometryGeneral PopulationGenesHerpes encephalitisHerpesviridaeHerpesvirus 1High PrevalenceHumanImmuneImmune responseImmunocompromised HostImmunohistochemistryImmunologicsImmunologyInfectionInfection ControlInflammasomeInflammationInflammatoryInnate Immune ResponseInnate Immune SystemIntegration Host FactorsInterleukin-1Interleukin-18InterventionKeratitisKnockout MiceKnowledgeLRRK2 geneLeadLearningLeprosyLesionLifeMalignant NeoplasmsMeasurableMeasuresMediatingMentorshipModelingMorbidity - disease rateMultiprotein ComplexesMusMutagenesisMutationNatural ImmunityNeuraxisOrganOutcomeParkinson DiseasePathogenesisPathogenicityPathologyPathway interactionsPopulationProductionRegulationResearch PersonnelResearch TrainingRoleSeveritiesSignal PathwaySignal TransductionSimplexvirusSkinSystemTestingTissuesTrainingTransfectionTransgenic MiceTumor-infiltrating immune cellsUnited StatesVaccinesViralViral EncephalitisViral PathogenesisVirulenceVirusVirus DiseasesVirus Replicationcareercareer developmentcell typechemokinecytokineimmune activationin vivomacrophagemarenostrinmortalitymouse LRRK2 proteinmouse modelmutantneurotropicneurotropic virusnovelnovel therapeuticspathogenprogramsresearch and developmentresponseskillsstable cell line
项目摘要
PROJECT SUMMARY
In the United States, herpes simplex virus type 1 (HSV-1) infects more than half the adult population and is the
leading cause of viral encephalitis and infectious blindness. Yet, the host factors contributing to the most
severe manifestations of HSV-1 remain unclear. Inflammasomes, a recently discovered antiviral innate
immune defense, and the production of two inflammasome cytokines (interleukin (IL)-1and IL-18) are critical
in HSV-1 control and pathogenesis. However, how inflammasomes are regulated during HSV-1 infection is
poorly understood. Recently, leucine-rich repeat kinase 2 (LRRK2) has emerged as a possible regulator of
inflammasome signaling. LRRK2 has been studied extensively because specific alleles are associated with
Parkinson’s disease, Crohn’s disease, cancer, and leprosy. Despite the disease associations, the precise
function of LRRK2 and how it mediates disease are unknown. Evidence for a role in the immune response
include that LRRK2 is highly expressed on immune cells, is upregulated in response to infection, and was
recently shown to modulate the NLRC4 inflammasome in response to bacterial infection. We recently
demonstrated that NLRP3 is critical in inflammasome activation by HSV-1, and our preliminary data indicate
that LRRK2 enhances NLRP3 signaling. We found that the common LRRK2 mutation G2019S enhances HSV-
1 pathology in mice without altering viral replication. These results point to a novel role for LRRK2 in
inflammasome signaling and HSV-1 pathogenesis. We hypothesize that LRRK2 modulates inflammasome
signaling in response to HSV-1 infection and that the G2019S mutation further enhances inflammasome
activation in vivo, leading to more severe eye, skin, and central nervous system (CNS) pathology after HSV-1
infection. LRRK2 has not been studied in human viral infection, and these represent the first studies to define
its role in the pathogenesis of a common neurotropic human viral infection. In Aim 1, we will identify how
LRRK2 associates with NLRP3, the critical inflammasome adapter in HSV-1 infection, and how mutations in
LRRK2 alter inflammasome signaling in the context of HSV-1 infection. We will accomplish this by using
targeted mutagenesis in a transfection model of inflammasome signaling and by studying inflammasome
activation after HSV-1 infection of cell lines stably expressing LRRK2 mutants. For Aim 2, we will determine
how LRRK2 alters the inflammasome response to HSV-1 using LRRK2 transgenic mice and mice with
inflammasome gene disruptions. Additionally, the PI will gain critical skills and expertise necessary to study the
innate immune response to HSV-1 and other herpesviruses. These learning objectives will be accomplished
through formal coursework, scientific programing, and direct mentorship by experts in viral and murine
immunology, herpesvirology, and biostatistics. The proposed career development plan and research aims will
provide a pathway to a career as an independent investigator studying the interactions between herpesviruses
and the innate immune system.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Hoover Karaba其他文献
Andrew Hoover Karaba的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Hoover Karaba', 18)}}的其他基金
Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2
富含亮氨酸重复激酶 2 对单纯疱疹病毒发病机制的调节
- 批准号:
10608136 - 财政年份:2021
- 资助金额:
$ 19.87万 - 项目类别:
Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2
富含亮氨酸重复激酶 2 对单纯疱疹病毒发病机制的调节
- 批准号:
10427420 - 财政年份:2021
- 资助金额:
$ 19.87万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 19.87万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 19.87万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 19.87万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 19.87万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 19.87万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 19.87万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 19.87万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 19.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 19.87万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 19.87万 - 项目类别: